Physician profile
Rishu Marwaha
NPI 1457490294
$4,102.31
in general payments reported to CMS, 2019-2025
36 companies · $44.99 in 2025
The $44.99 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $485 · 2021: $748 · 2022: $594 · 2023: $882 · 2024: $814 · 2025: $44.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,740.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $420.78 | 2019-2024 | |
| Amgen INC. | $327.42 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $322.29 | 2020-2025 | Freestyle Libre 3 |
| Pfizer INC. | $277.23 | 2019-2024 | |
| Lilly USA, LLC | $248.59 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Janssen Pharmaceuticals, INC | $199.67 | 2019-2021 | |
| Dexcom, INC. | $195.24 | 2021-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $191.38 | 2019-2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $171.49 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sanofi-Aventis U.S. LLC | $166.28 | 2020-2024 | |
| Abbvie INC. | $150.97 | 2020-2024 | |
| Medtronic, INC. | $130.75 | 2021-2023 | Minimed 770g |
| Novo Nordisk INC | $125.23 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $117.92 | 2024 | Farxiga |
| Astellas Pharma US INC | $101.26 | 2023-2024 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $95.41 | 2023 | Nuedexta, Rexulti |
| Amarin Pharma, INC. | $94.43 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $75.07 | 2021-2023 | Eliquis |
| Nestle Healthcare Nutrition INC. | $67.64 | 2021-2022 | |
| Eisai INC. | $64.44 | 2020-2021 | |
| Exact Sciences Corporation | $62.21 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $57.10 | 2022-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.30 | 2020-2024 | |
| Kyowa Kirin, INC. | $50.03 | 2023 | Crysvita |
| Mannkind Corporation | $49.94 | 2021-2023 | Afrezza |
| Alvogen INC | $49.22 | 2022 | |
| Avanir Pharmaceuticals, INC. | $40.32 | 2019-2021 | |
| Allergan, INC. | $33.83 | 2019 | |
| Radius Health, INC. | $25.05 | 2024 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $24.83 | 2021 | |
| Nevro Corp. | $23.73 | 2024 | Senza |
| Ultragenyx Pharmaceutical INC. | $22.43 | 2022 | |
| Tandem Diabetes Care, INC. | $19.92 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Inspire Medical Systems, INC. | $16.54 | 2024 | Inspire |
| Amryt Pharma Holdings LTD | $16.02 | 2022 | |
| Insulet Corporation | $14.35 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishu Marwaha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.